In the NEOPRISM-CRC trial, 32 patients with a specific genetic form of stage two or three bowel cancer received pembrolizumab before surgery instead of post-surgery chemotherapy. After nearly three years, none experienced recurrence, even those with traces of disease remaining a…
Immunotherapy Before Surgery Eliminates Recurrence in Bowel Cancer Trial
In the NEOPRISM-CRC trial, 32 patients with a specific genetic form of stage two or three bowel cancer received pembrolizumab before surgery instead of post-surgery chemotherapy. After nearly three years, none experienced recurrence, even those with traces of disease remaining after treatment.
Cancer immunotherapy · Wikimedia — licence per file · rights
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.